VICO — Vicore Pharma Holding AB Income Statement
0.000.00%
Last trade - 00:00- SEK1.97bn
- SEK1.48bn
Annual income statement for Vicore Pharma Holding AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 94 | 150 | 295 | 291 | 322 |
| Operating Profit | -94 | -150 | -295 | -291 | -322 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -93.3 | -147 | -297 | -289 | -311 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -93.1 | -147 | -296 | -288 | -311 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -93.1 | -147 | -296 | -288 | -311 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -93.1 | -147 | -296 | -288 | -311 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.16 | -2.71 | -4.25 | -3.99 | -2.8 |
| Dividends per Share |